Conivaptan Hydrochloride Injection
Injection
Current Active — Day 1522
FDA shortage record
- Substance
- Conivaptan Hydrochloride Injection
- Manufacturer
- Cumberland Pharmaceuticals Inc.
- Dosage form
- Injection
- Presentation
- Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)
- Therapeutic category
- Cardiovascular
- Package NDC
66220-160-10- Initially posted
- 03/14/2022
- Days on shortage list
- 1522
- Current FDA status
- Current
- Shortage entries (current dataset)
- 1 record for Conivaptan Hydrochloride Injection
Why this shortage matters
Cardiovascular drugs manage heart failure, arrhythmias, hypertension, and coronary artery disease. Shortages can disrupt stable long-term therapy or create gaps in acute care where dosing consistency is essential to preventing cardiac events.
FDA therapeutic class: Cardiovascular
Reason and context
Reason reported: Delay in shipping of the drug
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 615-255-0068.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.